InvestorsHub Logo
Followers 46
Posts 4459
Boards Moderated 0
Alias Born 07/26/2010

Re: None

Monday, 09/13/2021 11:23:22 AM

Monday, September 13, 2021 11:23:22 AM

Post# of 41
OVID 3.48 - setup for a freeroll???

$3 netcash-per-share?

Takeda, going forward, to incur all research expenses?

Two Phase-3-commencement announcement catalysts upcoming in 2021?

Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.

https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OVID News